France OKs sale of medical cannabis
The French drug safety agency has approved commercial sales of a medicine derived from cannabis for the first time in France.
France’s Health Ministry has said in a statement that sales of Sativex, produced by Britain’s GW Pharmaceuticals, will be allowed for the treatment of muscle spasms associated with multiple sclerosis.
Sativex contains marijuana’s two best known components – delta 9-THC and cannabidiol. The company’s website says the medicine has already been launched in 11 countries and approved in more than a dozen others.
A number of countries have been easing curbs on the sale of cannabis-based products for medical use in recent years, and the US state of Colorado allowed the nation’s first legal recreational marijuana shops to open starting this year.